Literature DB >> 9890105

Evaluation of patients with CNS involvement in SLE.

J G Hanly1.   

Abstract

Patients with systemic lupus erythematosus (SLE) may present with a wide array of neuropsychiatric (NP) clinical features. This may either be a primary manifestation of SLE, the result of a complication of the disease or its therapy, or a concurrent disease process. As there is no single diagnostic gold standard for NP-SLE, the assessment of individual patients is heavily dependent upon clinical evaluation in addition to information from studies of autoantibodies, brain structure and function. Despite their lack of diagnostic sensitivity and specificity, these tests frequently provide information that can be used to support or refute the clinical impression. They may also provide a basis for the prospective evaluation of the efficacy of therapeutic interventions in individual patients with NP-SLE.

Entities:  

Mesh:

Year:  1998        PMID: 9890105     DOI: 10.1016/s0950-3579(98)80028-9

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  5 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Antibody induction of lupus-like neuropsychiatric manifestations.

Authors:  David A Lawrence; Valerie J Bolivar; Chad A Hudson; Tapan K Mondal; Nina G Pabello
Journal:  J Neuroimmunol       Date:  2006-12-06       Impact factor: 3.478

Review 3.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 4.  New insights into central nervous system lupus: a clinical perspective.

Authors:  John G Hanly
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

Review 5.  Definition of NPSLE: Does the ACR Nomenclature Still Hold?

Authors:  Jessica Fernandes Vivaldo; Jaqueline Cristina de Amorim; Paulo Rogério Julio; Rodrigo Joel de Oliveira; Simone Appenzeller
Journal:  Front Med (Lausanne)       Date:  2018-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.